drugset / Trial / NCT05252520
A Study of JNJ-77474462 (Bermekimab) in Healthy Chinese Participants
NaSequentialOpen-labelOther
Summary
The purpose of this study is to assess the pharmacokinetics (PK) of JNJ-77474462 following single ascending dose subcutaneous (SC) administration to healthy Chinese participants.
Timeline
- Start
- 2023-05-01
- Primary completion
- 2023-11-20
- Completion
- 2023-11-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bermekimab | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.